Tvardi Therapeutics

TVRD

Market cap $29.1M

TVRD Hedge Fund Activity: Q1 2026 in Review

67 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2026, worth a combined $8.6M — down 29% from $12.1M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new TVRD positions and 12 closed out — a net gain of 2 holders — while 20 added to existing stakes and 17 trimmed.

The largest buyer was AQR Capital Management, opening a new position worth an estimated $165K. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.

• 67 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $8.6M of Tvardi Therapeutics stock for Q1 2026, down 29% quarter-over-quarter.
• 14 funds opened new Tvardi Therapeutics positions in Q1 2026 and 12 closed out, a net change of +2 holders.
• The largest Tvardi Therapeutics buyer in Q1 2026 was AQR Capital Management, an estimated $165K added.
• The largest Tvardi Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.

Based on aggregated 13F filings for Q1 2026.